ArticleJournal of immunology (Baltimore, Md. : 1950)2015
C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis.
Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 53 citations in OpenAlex.
- The Association of Prenatal C-Reactive Protein Levels With Childhood Asthma and Atopy.The journal of allergy and clinical immunology. In practice · 2022Trial
- Prediction of Response to Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?Cancers · 2026Review
- Article
- Association of novel inflammation markers derived from high-sensitivity C-reactive protein with anemia: a cross-sectional study based on NHANES 2015-2018.Thrombosis journal · 2026Article
- Prognostic impact of CRAFITY score in hepatocellular carcinoma patients treated with immune checkpoint inhibitors.iScience · 2025Article
- Review
- CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma.World journal of gastroenterology · 2025Article
- Biomarkers of inflammation and colorectal cancer risk.Frontiers in oncology · 2025Review
- m-EASIX (better than EASIX) predicts severe CAR T-cell toxicities, worse overall survival, and discriminates cytokine release syndrome from sepsis.Frontiers in immunology · 2025Article
- Utility of blood DNA methylation and immune cell-type estimates to identify clinically relevant links between immunity and health conditions in a large cohort.Frontiers in immunology · 2025Article
- Circulating CD4+, CD8+, and double-negative T cells in ischemic stroke and stroke-associated infection: a prospective case-control study.Frontiers in cellular neuroscience · 2025Article
- Article
- C-Reactive Protein Levels Correlate with Measures of Dysglycemia and Gut Microbiome Profiles.Current microbiology · 2023Article
- Prophylactic Coloprotective Effect ofMedicina (Kaunas, Lithuania) · 2023Article
- C-reactive protein impairs immune response of CD8Journal for immunotherapy of cancer · 2023Article
- C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians.Diseases (Basel, Switzerland) · 2023Review
- C-reactive protein and lactate dehydrogenase serum levels potentially predict the response to checkpoint inhibitors in patients with advanced non-small cell lung cancer.Journal of thoracic disease · 2023Article
- C-reactive protein deficiency ameliorates experimental abdominal aortic aneurysms.Frontiers in immunology · 2023Article
- Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers.Frontiers in immunology · 2023Article
- Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study.Hepatology international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
Human C-reactive protein (CRP) is a serum-soluble pattern recognition receptor that serves as a marker of inflammation and directly contributes to innate immunity. In this study, we show that human CRP also directly contributes to adaptive immunity, that is, native CRP binds specifically to human Jurkat T cells and to mouse naive CD4(+) T cells and modulates their Th1 and Th2 responses. In vitro both exogenously added (purified) and endogenously expressed (via transfection) human CRP inhibited Th1 differentiation and augmented Th2 differentiation of naive CD4(+) T cells. In vivo for human CRP transgenic compared with wild-type mice, a lesser proportion of the T cells recovered from the spleens of healthy animals were Th1 cells. Moreover, in both CRP transgenic mice and in wild-type mice treated with human CRP, during myelin oligodendrocyte glycoprotein peptide-induced experimental autoimmune encephalomyelitis both the Th1 cell response and disease severity were inhibited. These pattern recognition-independent actions of CRP directly on T cells highlights the potential for this soluble pattern recognition receptor to act as a tonic regulator of immunity, shaping global adaptive immune responses during both homeostasis and disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.